Search the Newsreel

[DVA Q2 2026 Earnings Call] DaVita to Roll Out Expanded Dialyzers Across Network, Lifts Volume Target to 50-75 Basis Points

DaVita reported Q2 2026 adjusted operating income of $579 million and adjusted EPS of $4.02, meeting expectations, with treatment volume growth accelerating to 56 basis points due to improved mortality. The company announced plans to broadly deploy newly FDA-approved expanded hemodialysis dialyzers following a …

DaVita falls despite top and bottom line beats

[Q2 second quarter business report infographic data] cagkansayin * DaVita (DVA [https://seekingalpha.com/symbol/DVA]) is down ~7% in after-hours trading Tuesday despite releasing Q2 financial results that beat [https://seekingalpha.com/news/4625305-davita-non-gaap-eps-of-4_02-beats-by-0_14-revenue-of-3_55b-beats-by-60m] on both lines and maintaining its 2026 guidance. * Adjusted diluted EPS for the year is seen …

Vitesse Energy Inc (VTS) (Q2 2026) Earnings Call Highlights: Record Production and Durable ... By GuruFocus

Vitesse Energy Inc (VTS) reported strong Q2 2026 results with record production averaging 17,354 BOE per day, a 9% sequential increase, and declared its 15th consecutive quarterly dividend. The company highlighted a strong balance sheet, effective hedging strategies extending into 2029, and improved capital …

Earnings call transcript: DaVita beats Q2 2026 estimates but shares fall

DaVita Inc. reported its Q2 2026 earnings, highlighting volume growth driven by improved patient mortality and better management of phosphate levels, though revenue per treatment declined due to lower commercial mix and binder revenue. The company is pivoting towards expanded hemodialysis technology and reconfirmed …

Vitesse Energy, Inc. (NYSE:VTS) Receives Average Recommendation of "Hold" from Analysts

Vitesse Energy, Inc. (NYSE:VTS) has received an average "Hold" recommendation from analysts, with a mixed outlook including buy, hold, and sell ratings. Despite trading near its 1-year low, the company announced a quarterly dividend yielding 11.3% annually. Insider and institutional ownership are significant, and …

DaVita Slides as Solid Q2 Results Fail to Lift Full-Year Outlook

DaVita (DVA) stock fell 9.1% despite solid second-quarter results, likely due to investors expecting a full-year guidance raise that did not materialize. The company reported increased revenue, earnings, and cash flow for Q2 2026 but maintained its previously issued full-year guidance. Factors such as …

DaVita (NYSE:DVA) Beats Q2 CY2026 Sales Expectations But Stock Drops

DaVita (NYSE:DVA) reported better-than-expected Q2 CY2026 revenue of $3.55 billion, a 5.2% year-on-year increase, and an adjusted EPS of $4.02, beating analyst estimates. Despite these positive results, the company's stock dropped by 9.8% to $210.75 immediately after the announcement, partly due to full-year EPS …

DaVita earnings beat by $0.18, revenue topped estimates

DaVita (NYSE: DVA) reported strong second-quarter results, beating analyst estimates with an EPS of $4.02 and revenue of $3.55 billion. The company also provided a positive outlook for fiscal year 2026, with an EPS guidance of $14.10-$15.20. DaVita's stock has shown significant growth, up …

No-Moat Revvity Sees Solid First-Half Performance With Momentum Likely to Continue

Revvity, formerly PerkinElmer, has demonstrated solid first-half performance in 2026, with strong earnings boosting its outlook. The company, which rebranded after divesting its applied, food, and enterprise services business, now focuses on diagnostics and life sciences. This positive momentum is expected to continue, driven …

DaVita reports Q2 2026 revenue of $3.55B, net i...

DaVita Inc. announced strong Q2 2026 results with consolidated revenues of $3.554 billion and net income attributable to DaVita of $265 million, an increase from $199 million in Q2 2025. The company's operating income rose to $579 million due to increased dialysis treatments and …

[10-Q] DAVITA INC. Quarterly Earnings Report

DaVita Inc. has filed its unaudited quarterly report (Form 10-Q) for the quarter ended June 30, 2026. Key financial highlights include share repurchases, an increase in Term Loan B-2 principal, and the recent acquisition of a minority interest in Elara Caring. The report details …

Earnings Flash (DVA) DaVita Inc. Reports Q2 Revenue $3.55B, vs. FactSet Est of $3.50B

DaVita Inc. (DVA) reported Q2 revenue of $3.55 billion, surpassing FactSet's estimate of $3.50 billion. The company also announced an adjusted EPS of $4.02 per share for Q2, exceeding the FactSet estimate of $3.88. Additionally, DaVita expects its full-year 2026 adjusted EPS to range …

Earnings Flash (DVA) DaVita Inc. Posts Q2 Adjusted EPS $4.02 per Share, vs. FactSet Est of $3.88

DaVita Inc. (DVA) announced Q2 adjusted earnings per share of $4.02, surpassing the FactSet estimate of $3.88. The company also reported Q2 revenue of $3.55 billion, exceeding the FactSet estimate of $3.50 billion. DaVita expects its full-year 2026 adjusted EPS to be in the …

DaVita reports Q2 2026: Revenue $3.554B, Operating income $579M, Diluted EPS $4.02

DaVita (DVA) reported its second-quarter 2026 financial results, with consolidated revenues reaching $3.554 billion, operating income at $579 million, and diluted earnings per share of $4.02. The company generated $490 million in operating cash flow and $256 million in free cash flow, while also …

DaVita Inc. 2nd Quarter 2026 Results

DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results," said Javier …

Revvity raises annual profit, revenue forecasts on strong diagnostics demand

Medical equipment maker Revvity has increased its annual profit and revenue forecasts after exceeding Wall Street expectations for the second quarter. This improvement is attributed to stronger demand for its drug-development tools and diagnostic testing products, with AI-related work contributing to incremental demand. Despite …

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity, Inc. (RVTY) reported strong second-quarter 2026 results, with adjusted EPS of $1.41 and revenues of $729.7 million, both surpassing analyst estimates, driven by strength in its Diagnostics segment. The company also raised its full-year 2026 pro forma outlook for revenues and adjusted EPS. …

DaVita earnings on deck as dialysis giant eyes value-based growth

DaVita HealthCare Partners Inc. is preparing to report its second-quarter earnings, with analysts anticipating strong performance driven by its shift towards value-based care. The company's Integrated Kidney Care platform and operational efficiencies, including an AI-enabled scheduling tool, are key areas of focus for investors. …

Revvity Inc (RVTY) (Q2 2026) Earnings Call Highlights: Strong Diagnostics Growth and Raised ...

This article first appeared on GuruFocus. Total Revenue: $711 million in Q2 2026, with pro forma organic growth of 3%. Adjusted EPS: $1.41, above the high end of guidance. Adjusted Operating Margin: 29.3% in the quarter, above the 27% outlook. Free Cash Flow: $184 …

Revvity outlines 2026 organic growth of 4% to 5% and adjusted EPS of $5.30 to $5.40, driven by diagnostics momentum and AI-linked demand

Earnings Call Insights: Revvity (RVTY) Q2 2026 MANAGEMENT VIEW * "I'm pleased to report that Revvity delivered strong results in the second quarter with pro forma organic growth of 3%, resulting in total revenue being above the high end of our expectations," said (CEO, …

Earnings call transcript: Revvity beats Q2 2026 estimates, but shares fall premarket

Revvity (RVTY) announced strong Q2 2026 results, exceeding adjusted EPS and revenue estimates, driven by organic growth, wider margins, and increased demand linked to AI. Despite the beat and raised full-year guidance for organic growth, operating margin, and EPS, the company's shares fell in …

48,310 Shares in Natural Grocers by Vitamin Cottage, Inc. $NGVC Purchased by Public Employees Retirement System of Ohio

Revvity Inc. stock underperforms Tuesday when compared to competitors

Revvity Inc. (RVTY) stock fell 3.32% on Tuesday, closing at $111.39, even as the broader market, including the S&P 500 Index and Dow Jones Industrial Average, saw significant gains. The company's stock was also 5.84% below its 52-week high reached on January 22nd.

Vitesse Energy, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:VTS) 2026-08-04

Revvity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 05, 2026

Revvity, Inc. announced its financial results for the second quarter and six months ended July 05, 2026. For the second quarter, sales increased to $729.69 million from $720.28 million year-over-year, while net income slightly decreased to $51.82 million. Diluted EPS for the quarter was …

DaVita Community Care Report 2025 : The Value of Community-Based Health Screenings

The DaVita Community Care Report for 2025 highlights the value of community-based health screenings, particularly for chronic kidney disease (CKD). In 2025, DaVita partnered with the YMCA to offer free health screenings and education in cities nationwide, resulting in over 1,200 screenings in Orlando, …

Revvity Tops Second-Quarter Estimates and Lifts Full-Year Outlook

Revvity, Inc. (NYSE:RVTY) reported strong second-quarter 2026 results, surpassing analyst expectations for both earnings and revenue. This performance led the health sciences company to raise its full-year guidance, with increased investments planned due to tariff refunds. The Diagnostics division was a key growth driver, …

Alert inadvertently tagged to Gravity Co Ltd withdrawn

MarketScreener has withdrawn an alert that was inadvertently tagged to Gravity Co., Ltd. The alert, published on August 4, 2026, at 07:59 am EDT, was initially associated with the company, which is known for developing and supplying game software, including mobile and online games …

VITL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vital Farms, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Vital Farms, Inc. (NASDAQ:VITL) on behalf of investors who suffered losses from May 8, 2025, to February 26, 2026. The lawsuit alleges that Vital Farms made false and misleading statements regarding delays …

Revvity Releases Q2 2026 Financial Results

Revvity, Inc. reported strong Q2 2026 financial results, exceeding Wall Street's EPS estimates by 12.8% with adjusted EPS of $1.41 and revenue of $729.7M. The Diagnostics segment led growth, and the company raised its full-year 2026 guidance for adjusted EPS and revenue, reflecting confidence …

Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates

Revvity (RVTY) reported strong Q2 results, with earnings of $1.41 per share and revenues of $729.69 million, both exceeding Zacks Consensus Estimates. The company has consistently surpassed EPS estimates over the last four quarters, and its stock has gained 19.1% year-to-date. Revvity currently holds …

Revvity deal to divest China immunodiagnostics; close expected 2027

Revvity (NYSE: RVTY) announced strong financial results for the second quarter of 2026, with adjusted EPS from continuing operations of $1.41, surpassing expectations. The company also entered a definitive agreement to divest its China Immunodiagnostics business, which represented approximately 6% of its fiscal year …

Revvity (NYSE:RVTY) Reports Upbeat Q2 CY2026

Revvity (NYSE:RVTY) reported strong Q2 CY2026 results, exceeding market expectations with a 7.2% year-on-year revenue increase to $729.7 million and non-GAAP EPS of $1.41, a 15.9% beat. The company also raised its full-year revenue and adjusted EPS guidance, indicating an encouraging outlook. Despite past …

Revvity beats estimates, raises guidance as stock jumps By Investing.com

Revvity, Inc. (NYSE:RVTY) reported strong second-quarter results, surpassing analyst expectations with adjusted EPS of $1.41 and revenue of $730 million. The health science solutions provider also raised its full-year 2026 guidance, projecting revenue of $2.83-$2.86 billion and pro forma adjusted EPS of $5.30-$5.40, driven …

Revvity (RVTY) Q2 2026 Earnings

Revvity (RVTY) reported strong Q2 2026 earnings, with EPS of $1.41 surpassing estimates by 15.9% and revenue of $730 million exceeding expectations by 3.8%. The Diagnostics segment was a key driver with 11% organic growth, offsetting a decline in Life Sciences. Management raised full-year …

Earnings Flash (RVTY) Revvity, Inc. Reports Q2 Revenue $729.7M, vs. FactSet Est of $703.0M

Revvity, Inc. (RVTY) announced its Q2 revenue of $729.7 million, surpassing FactSet's estimate of $703.0 million. The company also reported Q2 adjusted EPS of $1.41 per share, exceeding the FactSet estimate of $1.21. Furthermore, Revvity expects its full-year 2026 revenue to be in the …